New insights into the huntingtin protein, and further progress in turning genetic quirks that modify the course of HD into treatments, on the final day of the therapeutics conference
New tools to bridge the gap between the lab and patients in our update from day 2 of the 2019 HD Therapeutics conference
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
FDA grants “Investigational New Drug” status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntington’s Disease patients
Huntington's disease research news. In plain language. Written by scientists. For the global HD community.
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
HDSA's frequently asked questions factsheet about the huntingtin-lowering trial ASO program was so good we stole it (with permission)
Finally, a big study that shows what childhood HD looks like. This will help us work out if new drugs work in children too
The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease
The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.
As promised, HDBuzz's Jeff Carroll finally signed up for the Enroll-HD study. Learn more about this important global HD "observational study" here.